Skip to main content

Table 3 Cardiologic healthcare utilization in breast cancer patients in 2013ā€“2015

From: Healthcare utilization and hospital variation in cardiac surveillance during breast cancer treatment: a nationwide prospective study in 5000 Dutch breast cancer patients

Healthcare activities

NĀ =ā€‰5157

NĀ =ā€‰10,883

BC patients with high cardiotoxicity risk (%) a

BC patients with lower cardiotoxicity risk (%) a

Laboratory tests

ā€ƒTroponin I/T

5.1

3.8

ā€ƒBNP/ NT-proBNP

5.8

2.9

Imaging

ā€ƒCMR

0.7

0.2

ā€ƒEchocardiography

17.7

8.7

ā€ƒCT with coronary calcium score

0.4

0.2

ā€ƒCardiac nuclear imaging

27.7

1.2

ā€ƒā€ƒMUGA scan

26.5

0.4

Diagnostic tests

ā€ƒECG

52.0

26.5

ā€ƒExercise stress test

3.7

4.1

ā€ƒ24-h Holter monitoring

2.4

2.1

ā€ƒAngiography

0.4

0.5

ā€ƒā€ƒWith FFR

0.1

0.1

ā€ƒā€ƒWith IVUS

0.02

0

ā€ƒReveal

0.02

0.06

  1. aEach specific type of care is depicted with the percentage of patients for whom this type of care was registered at least once. BNP B-type Natriuretic Peptide, NT-proBNP N-terminal pro b-type Natriuretic Peptide, CMR Cardiovascular Magnetic Resonance, CT Computed Tomography, MUGA Multigated acquisition, ECG Electrocardiography, FFR Fractional Flow Reserve, IVUS Intravascular Ultrasound